The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Open accessAbstract
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. METHODS: In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. RESULTS: Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, 55% of patients in this trial did not have diabetes at baseline, and the effect of dapagliflozin was similar at any hemoglobin A1c level.40”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the secondary outcome of worsening kidney function (de fi ned as a sustained $ 50% reduction in eGFR, kidney failure, or death from kidney causes) occurred in 1.2% of the dapagli fl ozin arm and 1.6% of the placebo arm (HR: 0.71; 95% CI: 0.44 -1.16), which was not statistically signi fi cant ( P ¼ 0.17).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the DAPA-HF trial, major hypoglycemia, lower-limb amputation, and fracture occurred infrequently and the incidences were similar between the 2 treatment groups.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The lower risk of hospitalization for heart failure or death from cardiovascular causes in the dapagliflozin group than in the placebo group is consistent with the results of two previous trials of dapagliflozin, the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) and DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“SGLT2 inhibition is also known to benefit patients with heart failure and a reduced ejection fraction.471”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [471]
The cited source says what the claim attributes to it.
In the citing paper
“Over a median 18-month follow-up of 4744 patients with HFrEF, treatment with dapagliflozin significantly reduced the composite primary end point of time to first worsening of HF or death from CV causes (hazard ratio [HR], 0.74 [95% CI 0.65-0.85]; P < 0.001), as well as HHF (HR, 0.70 [95% CI 0.59 - 0.83]) and CV death (HR, 0.82 [95% CI 0.69 - 0.98]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“SGLT2 inhibitor treatment was safe with no excess in hypovolemia, hypoglycemia, or renal side effects compared with placebo.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“The primary outcome was similarly reduced for individuals with or without diabetes, with no effect of heterogeneity by diabetes status.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“The primary outcome was also similar among those with an eGFR $ 60 ml/min per 1.73 m 2 (HR: 0.76; 95% CI: 0.63 -0.92) or < 60 ml/min per 1.73 m 2 (HR: 0.72; 95% CI: 0.59 -0.86).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“the primary outcome of cardiovascular death, heart failure hospitalization, or urgent heart failure visit occurred in 16.3% of the dapagli fl ozin group and 21.2% of the placebo group (HR: 0.74; 95% CI: 0.65 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“However, notably, SGLT2i have been studied among patients without T2D who have CKD in the DAPA-CKD trial (and the soonto-be-published EMPA-KIDNEY trial) or who have heart failure (in the DAPA-HF, EMPEROR-Reduced, and EMPEROR-Preserved trials) and did not confer any increased risk of severe hypoglycemia or diabetic ketoacidosis among individuals without T2D.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“The effect of dapagliflozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (299).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
The cited source says what the claim attributes to it.
In the citing paper
“lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59-0.83]),”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
The cited source says what the claim attributes to it.
In the citing paper
“Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65-0.85]),”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
The cited source says what the claim attributes to it.
In the citing paper
“The effect of dapagliflozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (287).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [287]
The cited source says what the claim attributes to it.
In the citing paper
“Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65–0.85]), lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59–0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69–0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [287]
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalizations for heart failure in 8 large-scale trials, including those that focused on type 2 diabetes, heart failure with a reduced ejection fraction, and chronic kidney disease.1–8”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [6]
In the citing paper
“Rates of worsening heart failure or cardiovascular death are lower among patients with heart failure who are treated with dapagliflozin and empagliflozin regardless of diabetes diagnosis.7,8”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [7]
In the citing paper
“As for the morbidity, renal outcome and HHF, it was clear that SGLT-2i had more significant impact than finerenone, which might be explained by the special potency of SGLT-2i such as reducing blood glucose, reducing oxidative stress, losing weight, reducing uric acid, controlling blood pressure and improving renal ultrafiltration and hypoxia [65, 71–79].”
In the citing paper
“In DAPA-HF, dapagliflozin reduced the risk for worsening HF or CVD death irrespective of diabetes status (58).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [58]
In the citing paper
“Rates of heart failure hospitalization have been improved in recent trials including people with type 2 diabetes, most of whom also had ASCVD, with sodium -glucose cotransporter 2 (SGLT2) inhibitors (8 -11).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“Over a median of 18.2 months, the group assigned to dapagli fl ozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65 -0.85]), lower risk of fi rst worsening heart failure event (HR 0.70 [95% CI 0.59 -0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69 -0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“The effect of dapagli fl ozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (11).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“Over a median of 18.2 months, the group assigned to dapagli fl ozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65 -0.85]), lower risk of fi rst worsening heart failure event (HR 0.70 [95% CI 0.59 -0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69 -0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“Over a median of 18.2 months, the group assigned to dapagli fl ozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65 -0.85]), lower risk of fi rst worsening heart failure event (HR 0.70 [95% CI 0.59 -0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69 -0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure), the SGLT2 inhibitor dapagliflozin reduced the incidence of the primary composite outcome of cardiovascular death or worsening heart failure (HF) in patients who had HFrEF with and without type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [9]
In the citing paper
“The DAPA-HF trial randomly assigned patients with HFrEF with and without type 2 diabetes in a double-blind, placebo-controlled, event-driven trial.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,031
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 204
Singh, J. S., Mordi, I. R., Vickneson, K., Fathi, A., Donnan, P. T., Mohan, M., Choy, A. M., Gandy, S. J., Casella, G., Khan, F., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2187 · Cited by 182
Causland, F. R. M., Lefkowitz, M. P., Claggett, B. L., Anavekar, N. S., Senni, M., Gori, M., Jhund, P. S., McGrath, M. M., Packer, M., Shi, V. C., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047643 · Cited by 186
Self-citationSodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Joshi, S. S., Singh, T., Newby, D. E., & Singh, J. S. (2021) · Heart · doi:10.1136/heartjnl-2020-318060 · Cited by 191
Sex Differences in Heart Failure
Lala, A., Tayal, U., HAMO, C. E., Youmans, Q. R., Al‐Khatib, S. M., Bozkurt, B., Davis, M. B., Januzzi, J. L., Mentz, R. J., Sauer, A. J., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.10.006 · Cited by 189
Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases
Cai, J., Zhang, X., Ji, Y., Zhāng, P., She, Z., & Li, H. (2020) · Circulation Research · doi:10.1161/circresaha.119.316337 · Cited by 182
Heart failure with preserved ejection fraction
HAMO, C. E., DeJong, C., Hartshorne‐Evans, N., Lund, L. H., Shah, S. J., Solomon, S. D., & Lam, C. S. P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00540-y · Cited by 197
Self-citationExtraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s233538 · Cited by 199
Polypharmacy in Older Adults Hospitalized for Heart Failure
Ünlü, O., Levitan, E. B., Reshetnyak, E., Kneifati-Hayek, J. Z., Diaz, I. M., Archambault, A. N., Chen, L., Hanlon, J. T., Maurer, M. S., Safford, M. M., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.006977 · Cited by 177
Omar, M., Jensen, J., Ali, M., Frederiksen, P. H., Kistorp, C., Videbæk, L. M., Poulsen, M. K., Tuxen, C., Möller, S., Gustafsson, F., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6827 · Cited by 177
Self-citationMann, D. L., Givertz, M. M., Vader, J. M., Starling, R. C., Shah, P. M., McNulty, S. E., Anstrom, K. J., Margulies, K. B., Kiernan, M. S., Mahr, C., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.4567 · Cited by 177
Direct cardiac effects of SGLT2 inhibitors
Chen, S., Coronel, R., Hollmann, M. W., Weber, N. C., & Zuurbier, C. J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01480-1 · Cited by 177
Preventing CKD in Developed Countries
Luyckx, V. A., Cherney, D. Z. I., & Bello, A. K. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.12.003 · Cited by 189
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
der Beek, A. B. V. D. A., de Boer, R. A., & Heerspink, H. J. L. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00535-6 · Cited by 186
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
Porcari, A., Cappelli, F., Nitsche, C., Tomasoni, D., Sinigiani, G., Longhi, S., Bordignon, L., Masri, A., Serenelli, M., Urey, M. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.429 · Cited by 179
Self-citationJackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047077 · Cited by 175
Self-citationEpidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 186
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Sattar, N. A., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.033 · Cited by 172
Savarese, G., Bodegård, J., Norhammar, A., Sartipy, P., Thuresson, M., Cowie, M., Fonarow, G. C., Vaduganathan, M., & Coats, A. J. S. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2271 · Cited by 177
Ezekowitz, J. A., Colin-Ramirez, E., Ross, H., Escobedo, J., Macdonald, P., Troughton, R., Saldarriaga, C., Alemayehu, W., McAlister, F. A., Arcand, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00369-5 · Cited by 179
Self-citationAllen, L. A., Venechuk, G. E., McIlvennan, C. K., Page, R. L., II, Knoepke, C. E., Helmkamp, L. J., Khazanie, P., Peterson, P. N., Pierce, K., Harger, G., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051863 · Cited by 171
Dyck, J. R. B., Sossalla, S. T., Hamdani, N., Coronel, R., Weber, N. C., Light, P. E., & Zuurbier, C. J. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.03.005 · Cited by 181
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 180
Self-citationAdhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R. S., Eckel, R. H., Alexander, G. C., & Blaha, M. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023811 · Cited by 166
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
Ferreira, J. P., Zannad, F. M., Pocock, S., Anker, S. D., Butler, J., Filippatos, G. S., Brueckmann, M., Jamal, W., Steubl, D., Schueler, E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.044 · Cited by 168
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167
Schernthaner, G., Shehadeh, N., As, A., Bazarova, A., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalic, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 163
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-5938 · Cited by 171
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Butt, J. H., Dewan, P., Merkely, B. P., Bělohlávek, J., Dróżdż, J., Kitakaze, M., Inzucchi, S. E., Kosiborod, M., Martínez, F. A., Tereshchenko, S. N., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4776 · Cited by 163
Self-citationBassi, N. S., Ziaeian, B., Yancy, C. W., & Fonarow, G. C. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0898 · Cited by 163
Gongora, C. A., Drobni, Z. D., Silva, T. Q. A. C., Zafar, A., Gong, J., Zlotoff, D. A., Gilman, H. K., Hartmann, S. E., Sama, S., Nikolaidou, S., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.03.006 · Cited by 161
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S. C., & Liberale, L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae047 · Cited by 210
Packer, M., & McMurray, J. J. V. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2149 · Cited by 169
Self-citationYamada, T., Wakabayashi, M., Bhalla, A., Chopra, N., Miyashita, H., Mikami, T., Ueyama, H. A., Fujisaki, T., Saigusa, Y., Yamaji, T., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01197-z · Cited by 170
Cardoso, R. N., Graffunder, F. P., Ternes, C. M. P., Fernandes, A. D. F., Rocha, A. V., Fernandes, G. C., & Bhatt, D. L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100933 · Cited by 170
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 166
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Marx, N., Davies, M. J., Grant, P. J., Mathieu, C., Petrie, J. R., Cosentino, F., & Buse, J. B. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30343-0 · Cited by 160
Müllens, W., Auricchio, A., Martens, P., Witte, K. K., Cowie, M., Delgado, V., Dickstein, K., Linde, C. M., Vernooy, K., Leyva, F., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2046 · Cited by 165
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
Boorsma, E. M., Beusekamp, J. C., ter Maaten, J. M., Figarska, S. M., Danser, A. H. J., van Veldhuisen, D. J., van der Meer, P., Heerspink, H. J. L., Damman, K., & Voors, A. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2066 · Cited by 165
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Usman, M., Siddiqi, T. J., Anker, S. D., Bakris, G. L., Bhatt, D. L., Filippatos, G. S., Fonarow, G. C., Greene, S. J., Januzzi, J. L., Khan, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.034 · Cited by 170
Self-citationAssociation of metabolic syndrome and chronic kidney disease
Scurt, F. G., Ganz, M. J., Herzog, C., Bose, K., Mertens, P. R., & Chatzikyrkou, C. (2024) · Obesity Reviews · doi:10.1111/obr.13649 · Cited by 155
Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond
Sun, Q., Karwi, Q. G., Wong, N. K. P., & Lopaschuk, G. D. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae231 · Cited by 164
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
Metformin, Macrophage Dysfunction and Atherosclerosis
Feng, X., Chen, W., Ni, X., Little, P. J., Xu, S., Tang, L., & Weng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682853 · Cited by 156
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Docherty, K. F., Welsh, P. I., Verma, S., de Boer, R. A., O’Meara, E., Bengtsson, O., Køber, L., Kosiborod, M., Hammarstedt, A., Langkilde, A. M., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060511 · Cited by 154
Self-citationPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Sabatino, J., Rosa, S. D., Tammè, L., Iaconetti, C., Sorrentino, S., Polimeni, A., Mignogna, C., Amorosi, A., Spaccarotella, C., Yasuda, M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01040-5 · Cited by 151
Müllens, W., Martens, P., Testani, J. M., Tang, W. H. W., Skouri, H. N., Verbrugge, F. H., Fudim, M., Iacoviello, M., Franke, J., Flammer, A. J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2471 · Cited by 154
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Cox, Z. L., Collins, S. P., Hernandez, G. A., McRae, A. T., Davidson, B. T., Adams, K. F., Aaron, M. F., Cunningham, L. C., Jenkins, C. A., Lindsell, C. J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.009 · Cited by 157
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan
Solomon, S. D., Jhund, P. S., Claggett, B. L., Dewan, P., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., Inzucchi, S. E., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.04.008 · Cited by 147
Self-citationPandey, A. K., Okaj, I., Kaur, H., Belley‐Côté, E. P., Wang, J., Oraii, A., Benz, A. P., Johnson, L., Young, J., Wong, J. A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022222 · Cited by 156
Self-citationDiagnosis and Treatment of Type 2 Diabetes in Adults
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 145
McEwan, P. C., Darlington, O. T., McMurray, J. J. V., Jhund, P. S., Docherty, K. F., Böhm, M., Petrie, M. C., Bergenheim, K., & Qin, L. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1978 · Cited by 151
Self-citationYurista, S. R., Matsuura, T. R., Silljé, H. H. W., Nijholt, K. T., McDaid, K. S., Shewale, S. V., Leone, T. C., Newman, J. C., Verdin, E. M., van Veldhuisen, D. J., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007684 · Cited by 144
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Glucose transporters in the kidney in health and disease
Vallon, V. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02361-w · Cited by 152
McMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa‐Rotter, R., Chertow, G. M., Greene, T., Held, C., Hou, F. F., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051675 · Cited by 151
Self-citationCoronary blood flow in heart failure: cause, consequence and bystander
Heusch, G. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00909-8 · Cited by 147
Divakaruni, A. S., & Jastroch, M. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00619-4 · Cited by 162
Pugliese, N. R., Pellicori, P., Filidei, F., Biase, N. D., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac133 · Cited by 150
Paolisso, P., Bergamaschi, L., Gragnano, F., Gallinoro, E., Cesaro, A., Sardu, C., Mileva, N. B., Foà, A., Armillotta, M., Sansonetti, A., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106597 · Cited by 144
Mitochondrial dysfunction and mitochondrial therapies in heart failure
Wu, C., Zhang, Z., Zhang, W., & Liu, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106038 · Cited by 148
Serenelli, M., Böhm, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., DeMets, D. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa496 · Cited by 138
Self-citationBakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10140620 · Cited by 142
Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification
Hilvo, M., Vasile, V. C., Donato, L. J., Hurme, R., & Laaksonen, R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.570628 · Cited by 147
Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4
Díez, J., González, A., & Kovacic, J. C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.019 · Cited by 147
Teo, Y. H., Teo, Y. N., Syn, N. L. X., Kow, C. S., Yoong, C. S. Y., Tan, B. Y., Yeo, T., Lee, C., Lin, W., & Sia, C. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019463 · Cited by 141
Adamson, C., Docherty, K. F., Heerspink, H. J. L., de Boer, R. A., Damman, K., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Petrie, M. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058910 · Cited by 139
Self-citationKhan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Self-citationPolypharmacy definition and prevalence in heart failure: a systematic review
Beezer, J., AlHatrushi, M. S., Husband, A., Kurdi, A. B., & Forsyth, P. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10135-4 · Cited by 139
Management of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction Patients
Cautela, J., Tartière, J., Solal, A. C., Bellemain-Appaix, A., Théron, A., Tibi, T., Januzzi, J. L., Roubille, F., & Girerd, N. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1835 · Cited by 143
Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Systematic Review and Meta-Analysis
Butler, J., Usman, M., Khan, M. S., Greene, S. J., Friede, T., Vaduganathan, M., Filippatos, G. S., Coats, A. J. S., & Anker, S. D. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13169 · Cited by 145
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Perreault, L., Skyler, J. S., & Rosenstock, J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00489-y · Cited by 145
Cardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 158
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation
Raposeiras‐Roubín, S., Amat-Santos, I. J., Rosselló, X., González-Ferreiro, R., Bermúdez, I. G., López‐Otero, D., y, L. N.-F., Gheorghe, L. L., Diez, J. L., Baladrón, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2500366 · Cited by 142
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 141
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Rocca, H. B., Janssens, S. P., Tsutsui, H., Zhang, J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa968 · Cited by 139
Kwan, T., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., DEEDWANIA, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 140
Mitochondrial Mechanisms in Diabetic Cardiomyopathy
Gollmer, J., Zirlik, A., & Bugger, H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0185 · Cited by 139
Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
Cuijpers, I., Simmonds, S. J., van Bilsen, M., Czarnowska, E., González, A., Heymans, S. R. B., Kuhn, A.-R., Mulder, P. G. H., Ratajska, A., Jones, E. A. V., et al. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-0798-y · Cited by 144
Peikert, A., Martínez, F. A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., de Boer, R. A., DeMets, D. L., Hernandez, A. F., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010080 · Cited by 151
Self-citationSGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Saisho, Y. (2020) · Diseases · doi:10.3390/diseases8020014 · Cited by 145
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
Marton, A., Kaneko, T., Kovalik, J., Yasui, A., Nishiyama, A., Kitada, K., & Titze, J. M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00350-x · Cited by 136
Anker, S. D., Butler, J., Filippatos, G. S., Khan, M. S., Ferreira, J. P., Bocchi, E. A., Böhm, M., Rocca, H. B., Choi, D., Chopra, V., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2064 · Cited by 146
Self-citationMarfella, R., Scisciola, L., D’Onofrio, N., Maiello, C., Trotta, M. C., Sardu, C., Panarese, I., Ferraraccio, F., Capuano, A., Barbieri, M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106448 · Cited by 136
Dapagliflozin in patients with heart failure and reduced ejection fraction
(GrAM), G. D. A. M., Colombo, G., Casella, R., Cazzaniga, A., & Casiraghi, C. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02297-0 · Cited by 134
‘Time is Prognosis’ in Heart Failure: Time-to-Treatment Initiation as a Modifiable Risk Factor
Abdin, A., Anker, S. D., Butler, J., Coats, A. J. S., Kindermann, I., Lainščak, M., Lund, L. H., Metra, M., Müllens, W., Rosano, G. M. C., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13646 · Cited by 137
Self-citationSex and gender differences in myocarditis and dilated cardiomyopathy: An update
Fairweather, D., Beetler, D. J., Musigk, N., Heidecker, B., Lyle, M. A., Cooper, L. T., & Bruno, K. A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1129348 · Cited by 124
Seferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1954 · Cited by 136
Self-citationEmergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 140
Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity
Iacobellis, G., & Gra‐Menendez, S. (2020) · Obesity · doi:10.1002/oby.22798 · Cited by 130
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.003 · Cited by 135
Durante, W., Behnammanesh, G., & Peyton, K. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168786 · Cited by 135
Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R. A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., Angelis, A. D., Sportiello, L., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1008922 · Cited by 135
Tomasoni, D., Fonarow, G. C., Adamo, M., Anker, S. D., Butler, J., Coats, A. J. S., Filippatos, G. S., Greene, S. J., McDonagh, T. A., Ponikowski, P. P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2397 · Cited by 138
Self-citationUsman, M., Bhatt, D. L., Hameed, I., Anker, S. D., CHENG, A. Y. Y., Hernandez, A. F., Jones, W. S., Khan, M. S., Petrie, M. C., Udell, J. A., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00102-5 · Cited by 148
Self-citationTheodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 149
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 132
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 147
Self-citation
Metadata
- Authors
- McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., Howlett, J. G., Katova, T., Kitakaze, M., Ljungman, C. E. A., Merkely, B., Nicolau, J. C., O’Meara, E., Petrie, M. C., Vinh, P. N., Schou, M., Tereshchenko, S., Verma, S., Held, C., DeMets, D. L., Docherty, K. F., Jhund, P. S., Bengtsson, O., Sjöstrand, M., & Langkilde, A.-M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (J.J.V.M., M.C.P., K.F.D., P.S.J.); the Cardiovascular Division (S.D.S., A.S.D.) and the TIMI Study Group, Brigham and Women’s Hospital and Harvard Medical School (M.S.S.) — all in Boston; Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.); Rigshospitalet Copenhagen University Hospital (L.K.) and the Department of Cardiology, Gentofte University Hospital (M. Schou),...
- Semmelweis University (HU)
- Uppsala University (SE)
- ORCID
- McMurray, John J.V.
- Solomon, Scott D.
- Inzucchi, Silvio E.
- Køber, Lars
- Kosiborod, Mikhail N.
- Ponikowski, Piotr
- Sabatine, Marc S.
- Anand, Inder S.
- Bělohlávek, Jan
- Böhm, Michael
- Chiang, Chern-En
- Chopra, Vijay K.
- Desai, Akshay S.
- Ge, Junbo
- Howlett, Jonathan G.
- Kitakaze, Masafumi
- Ljungman, Charlotta E.A.
- Merkely, Béla
- O’Meara, Eileen
- Petrie, Mark C.
- Schou, Morten
- Tereshchenko, Sergey
- Verma, Subodh
- Held, Claes
- DeMets, David L.
- Docherty, Kieran F.
- Jhund, Pardeep S.
- Bengtsson, Olof
- Sjöstrand, Mikaela
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 1995-2008
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2974260792
- Semantic Scholar
- 43e5c9ff37bb98a622e70cb01c55e23a60782d69
- Cited by
- 7,140
- References
- 21
- Citations by year
- 2026: 842 · 2025: 955 · 2024: 979 · 2023: 1060 · 2022: 1138 · 2021: 1152 · 2020: 904 · 2019: 89
- FWCI
- 593.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Research Bank (Australian Catholic University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca Plc
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure with reduced ejection fraction, type 2 diabetes, cardiovascular mortality, heart failure hospitalization, hypovolemia, renal dysfunction, hypoglycemia, SGLT2 inhibition, heart failure prognosis, adverse events, glucose monitoring, heart failure with preserved ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Cardiovascular Agents, Cardiovascular Diseases, Combined Modality Therapy, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glucosides, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Ventricular Dysfunction, Left, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
